How to ensure accurate NeuroQuant® processing results

In this post, I review additional causes affecting goodness of fit which can result in NeuroQuant being unable to segment specific brain structures and issuing a processing error message. Previous posts discussed why contrast agents are not used to achieve quality segmentation with NeuroQuant, and examined why good alignment to atlas is necessary for accurate NeuroQuant output.

Ensuring proper processing is an important factor in NeuroQuant’s analysis process. To achieve its high quality segmentation results, NeuroQuant verifies each patient’s brain image can be processed correctly. This safeguards the accuracy of the segmentation results and therefore, the accuracy of the calculated volumes.

Patients who have shunts, implants or other artifacts or inherent abnormalities, can potentially generate segmentation misregistration. To prevent such errors and protect the accuracy of the results, NeuroQuant prevents analysis when such artifacts or anatomical anomalies are present.

In some cases, such as the first example below, a shunt in the patient’s brain made good alignment to atlas impossible, resulting in a processing failure.

Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing resultsIn the second example, a patient’s excess cranial tissue prevented proper processing and resulted in an error message.

Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing resultsMore information about using and processing NeuroQuant can be found here.

More Resources

04/02/2025

Pediatric Neuroimaging Insights: The NeuroQuant® Age Range Series

Brain volumetrics play a pivotal role in understanding pediatric neurological development. Explore how NeuroQuant® enhances neuroimaging from ages 3 to 100.

03/31/2025

How NeuroAlign CT Subtraction Maps Enhance Detection and Confidence in Neuroradiology

What if head CT assessment could be even faster and more accurate? Subtraction maps allow for improved detection and visualization of subtle interval changes.

03/27/2025

Cortechs.ai Joins Forces with Kryptonite Solutions as a Distribution Partner to Expand AI-Driven Neuroimaging Access in India

We are pleased to announce a strategic partnership with Kryptonite Solutions to distribute our innovative portfolio across India.

03/20/2025

Cortechs.ai Announces Strategic Distribution Partnership with Medical Horizons to Expand Presence in Italy, Turkey, and the Middle East

We are pleased to announce a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy.

03/18/2025

Unlocking the Power of AI Imaging in Multiple Sclerosis: How NeuroQuant® MS Enhances Lesion Detection and Monitoring

Unlock the power of AI-driven imaging with NeuroQuant® MS—enhancing lesion detection, monitoring, and personalized care for Multiple Sclerosis.

03/09/2025

Advancing TBI Evaluation with AI-Driven MRI Analysis: A New Era in Brain Health

AI-driven MRI with NeuroQuant® enhances TBI assessment, tracks recovery, and supports better treatment decisions.
Scroll to Top